<div class="pk-crumbs" data-crumbs="[{&quot;label&quot;:&quot;Drugs&quot;,&quot;href&quot;:&quot;README.md&quot;},{&quot;label&quot;:&quot;C01B&quot;,&quot;href&quot;:&quot;atc/C01B.md&quot;},{&quot;label&quot;:&quot;bretylium tosilate&quot;}]"></div>
<div class="pk-recnav" data-items="[{&quot;id&quot;:&quot;BretyliumTosilate_Garrett1982_reference&quot;,&quot;label&quot;:&quot;Garrett_1982_reference&quot;,&quot;href&quot;:&quot;drugs/drug_bretylium_tosilate/BretyliumTosilate_Garrett1982_reference.md&quot;,&quot;status&quot;:&quot;needs review&quot;,&quot;css&quot;:&quot;pk-badge--orange&quot;,&quot;here&quot;:false},{&quot;id&quot;:&quot;BretyliumTosilate_Kamath1981_reference&quot;,&quot;label&quot;:&quot;Kamath_1981_reference&quot;,&quot;href&quot;:&quot;drugs/drug_bretylium_tosilate/BretyliumTosilate_Kamath1981_reference.md&quot;,&quot;status&quot;:&quot;needs review&quot;,&quot;css&quot;:&quot;pk-badge--orange&quot;,&quot;here&quot;:false},{&quot;id&quot;:&quot;BretyliumTosilate_Narang1980_reference&quot;,&quot;label&quot;:&quot;Narang_1980_reference&quot;,&quot;href&quot;:&quot;drugs/drug_bretylium_tosilate/BretyliumTosilate_Narang1980_reference.md&quot;,&quot;status&quot;:&quot;rejected&quot;,&quot;css&quot;:&quot;pk-badge--red&quot;,&quot;here&quot;:false},{&quot;id&quot;:&quot;BretyliumTosilate_Rapeport1985_reference&quot;,&quot;label&quot;:&quot;Rapeport_1985_reference&quot;,&quot;href&quot;:&quot;drugs/drug_bretylium_tosilate/BretyliumTosilate_Rapeport1985_reference.md&quot;,&quot;status&quot;:&quot;rejected&quot;,&quot;css&quot;:&quot;pk-badge--red&quot;,&quot;here&quot;:false}]"></div>

# bretylium tosilate

- **generic name:** bretylium tosilate
- **ATC codes:** `C01BD02`
- **DrugBank:** [DB01158](https://go.drugbank.com/drugs/DB01158) · **PubChem:** [CID 2431](https://pubchem.ncbi.nlm.nih.gov/compound/2431)
- **molar mass:** 243.163 g/mol (C11H17BrN) — DrugBank
- **groups:** approved

## About

**Description.** Bretylium blocks the release of noradrenaline from the peripheral sympathetic nervous system, and is used in emergency medicine, cardiology, and other specialties for the acute management of ventricular tachycardia and ventricular fibrillation. The primary mode of action for bretylium is thought to be inhibition of voltage-gated K(+) channels. Recent evidence has shown that bretylium may also inhibit the Na,K-ATPase by binding to the extracellular K-site.

**Indication.** For use in the prophylaxis and therapy of ventricular fibrillation. Also used in the treatment of life-threatening ventricular arrhythmias, such as ventricular tachycardia, that have failed to respond to adequate doses of a first-line antiarrhythmic agent, such as lidocaine.

## Extraction summary

| extracted at | time | popPK e/r/o | PD e/r/o (paper) | PGx e/r/o | tokens in/out | LLM | papers | GROBID/JATS | OA/non-OA | NONMEM |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-19 14:57 | 3:21 | 1/2/1 | 0/1/0 | 0/0/0 | 81,994/6,783 | ollama / qwen3.8:27b-mtp-q8_0 | 1 | 1/0 | 1/0 | 0 |

## popPK records

| status | detail | model | model structure | params | citation | doi |
|---|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--orange">needs review</span><br><sub>blocking: disposition incomplete — only volume extracted — the engineer needs both; the m…</sub><br><sub>blocking: C5 dimensioned parameter(s) without a unit: Q65 — no SI value to build from</sub><br><sub>route_to: `human_review`</sub> | [Garrett_1982_reference](drugs/drug_bretylium_tosilate/BretyliumTosilate_Garrett1982_reference.md) | — | 1-compartment (no model) | 4 | Garrett ER et al., Bretylium pharmacokinetics and bioavail…, Biopharmaceutics & drug dis… (1982) | [10.1002/bdd.2510030206](https://doi.org/10.1002/bdd.2510030206) |
| <span class="pk-badge pk-badge--orange">needs review</span><br><sub>blocking: T6_deviations</sub><br><sub>route_to: `engineer`</sub> | [Kamath_1981_reference](drugs/drug_bretylium_tosilate/BretyliumTosilate_Kamath1981_reference.md) | ▶ model + simulator | 2-compartment, oral | 6 | Kamath BL et al., Pharmacokinetics of [14C]bretylium tosy…, Journal of pharmaceutical s… (1981) | [10.1002/jps.2600700623](https://doi.org/10.1002/jps.2600700623) |
| <span class="pk-badge pk-badge--red">rejected</span><br><sub>blocking: C5 dimension mismatch on a structural parameter</sub><br><sub>route_to: `human_review`</sub> | [Narang_1980_reference](drugs/drug_bretylium_tosilate/BretyliumTosilate_Narang1980_reference.md) | — | 1-compartment (no model) | 3 | Narang PK et al., Pharmacokinetics of bretylium in man af…, Journal of pharmacokinetics… (1980) | [10.1007/BF01059384](https://doi.org/10.1007/BF01059384) |
| <span class="pk-badge pk-badge--red">rejected</span><br><sub>blocking: missing key parameters — none reported by this paper</sub><br><sub>route_to: `human_review`</sub> | [Rapeport_1985_reference](drugs/drug_bretylium_tosilate/BretyliumTosilate_Rapeport1985_reference.md) | — | 1-compartment (no model) | 0 | Rapeport WG, Clinical pharmacokinetics of bretylium, Clinical pharmacokinetics (1985) | [10.2165/00003088-198510030-00004](https://doi.org/10.2165/00003088-198510030-00004) |

## Pharmacodynamics (PD)

| status | detail | about | model | citation | doi |
|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--red">rejected</span> | [Sakuta_1993_unknown](drugs/drug_bretylium_tosilate/pd_Sakuta_1993_unknown.md) | Y-26763-induced K+ current ← clofilium · inhibition effect | — | Sakuta H et al., Antiarrhythmic drugs, clofilium and cib…, British journal of pharmaco… (1993) | [10.1111/j.1476-5381.1993.tb13655.x](https://doi.org/10.1111/j.1476-5381.1993.tb13655.x) |

## ADME sites

Where this drug is handled, from DrugBank's curated enzymes / transporters / carriers and the KB's PGx genes, mapped to tissue through the ADME gene table. Compare it with other drugs on the [Sites & interactions](sites?drugs=bretylium_tosilate) page (add drugs there; the set becomes a link).

| process | tissue | actors (role) | evidence |
|---|---|---|---|

<sub>Actors without a tissue in the table: ADRB1 (target), ATP1A1 (inhibitor).</sub>

<details class="legend">
<summary>Badge legend — what each badge means</summary>
<table><thead><tr><th>badge</th><th>what it means</th></tr></thead><tbody><tr><td><span class="pk-badge pk-badge--green">curated</span></td><td>hand-authored by a person — an exemplar, not an extraction.</td></tr><tr><td><span class="pk-badge pk-badge--green">extracted</span></td><td>the pipeline accepted the record: every closed-form check it could run passed.</td></tr><tr><td><span class="pk-badge pk-badge--green">reviewed — candidate</span></td><td>the reviewer ran the built model against the paper's own reported values and they agree — the best automatic verdict there is.</td></tr><tr><td><span class="pk-badge pk-badge--green">accepted (caveats)</span></td><td>the model replicates the paper, but an advisory check failed — the record page names the caveat under the badge and the drug page shows it under the status.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>extracted, then a check failed or a value looks implausible. The numbers are shown as read, not endorsed.</td></tr><tr><td><span class="pk-badge pk-badge--orange">built, not shipped</span></td><td>a model was built, but a core parameter fell back to a library default, so it is not shipped.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>not accepted — the record is not a compartmental model, or nothing usable was extracted.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">not modelled</span></td><td>pipeline state, not a judgement: no model has been built for this record yet (likewise `not simulated`).</td></tr><tr><td><span class="pk-badge pk-badge--stale">stale</span></td><td>the reviewer's verdict predates the latest re-run of the paper — treat the status as out of date, not as current.</td></tr><tr><td><span class="pk-badge pk-badge--green">cross-checked ✓</span></td><td>every independent reader agreed on every compared field. With more than one reader the badge counts them, e.g. 'cross-checked ✓ 2/2'.</td></tr><tr><td><span class="pk-badge pk-badge--orange">cross-check: partial</span></td><td>a reader differs on a non-structural field (a population label, a flag), or the readers do not all agree with each other.</td></tr><tr><td><span class="pk-badge pk-badge--red">cross-check: disputed</span></td><td>at least one reader differs on a structural parameter — a clearance, a volume, ka, a lag. The record still holds the FIRST reading; the disagreement is a signal for a reviewer, never an automatic correction.</td></tr></tbody></table>
<p><small>The first badge is the record's <b>status</b> — what the pipeline and the reviewer concluded. A second badge, when present, is the <b>cross-check</b>: whether a model of another family, re-reading the same paper, extracted the same numbers. They are independent — a rejected record can be cross-checked, and a confirmed reading can still fail a plausibility check.</small></p>
</details>

## Coverage

- **PubMed hits:** 11 matched, 11 returned
- **screened:** 5  ·  **relevant:** 5
- **records:** 4  ·  extracted 0  ·  needs_review 2  ·  rejected 2  ·  stale 0
- **scholar-agent fallback query used:** not captured

## Full text wanted

_7 paper(s) judged relevant from the abstract, with no full text on disk — paywalled, or the resolver could not reach them. Follow the DOI, then save the PDF into `papers/` as `&lt;save as&gt;.pdf` and re-run the extraction._

| save as | citation | domain | score | DOI | PubMed | why wanted |
|---|---|---|---|---|---|---|
| `Garrett_1982.pdf` | Garrett ER et al., Bretylium pharmacokinetics and bioavail…, Biopharmaceutics & drug dis… (1982) | popPK | 10 | [10.1002/bdd.2510030206](https://doi.org/10.1002/bdd.2510030206) | [7104462](https://pubmed.ncbi.nlm.nih.gov/7104462) | The paper reports quantitative pharmacokinetic parameters (half-lives, clearance, volume of distribution) for bretylium tosylate in humans and dogs, with all numeric values explicitly present in the text. |
| `Kamath_1981.pdf` | Kamath BL et al., Pharmacokinetics of [14C]bretylium tosy…, Journal of pharmaceutical s… (1981) | popPK | 10 | [10.1002/jps.2600700623](https://doi.org/10.1002/jps.2600700623) | [7252812](https://pubmed.ncbi.nlm.nih.gov/7252812) | The paper reports quantitative pharmacokinetic parameters (Vd, CL, half-life) for bretylium tosylate in rats with all numeric values explicitly present in the text. |
| `Kamath_1982.pdf` | Kamath BL et al., Pharmacokinetics of bretylium in dogs a…, Journal of pharmaceutical s… (1982) | popPK | 10 | [10.1002/jps.2600711129](https://doi.org/10.1002/jps.2600711129) | [7175729](https://pubmed.ncbi.nlm.nih.gov/7175729) | The study reports quantitative pharmacokinetic parameters (half-lives, volumes, clearances) for bretylium tosylate in dogs, with all numeric values explicitly present in the text. |
| `Narang_1980.pdf` | Narang PK et al., Pharmacokinetics of bretylium in man af…, Journal of pharmacokinetics… (1980) | popPK | 10 | [10.1007/BF01059384](https://doi.org/10.1007/BF01059384) | [7431227](https://pubmed.ncbi.nlm.nih.gov/7431227) | The paper reports quantitative pharmacokinetic parameters (half-life, volume of distribution, clearance) for bretylium tosylate in humans, with specific numeric values provided in the text. |
| `Rapeport_1985.pdf` | Rapeport WG, Clinical pharmacokinetics of bretylium, Clinical pharmacokinetics (1985) | popPK | 9 | [10.2165/00003088-198510030-00004](https://doi.org/10.2165/00003088-198510030-00004) | [3893841](https://pubmed.ncbi.nlm.nih.gov/3893841) | The abstract provides specific quantitative pharmacokinetic parameters for bretylium, including bioavailability (18-23%), clearance (~600 ml/min), and half-life (7-11 hours). |
| `Wilson_2004.pdf` | Wilson TE et al., Effect of age on cutaneous vasoconstric…, American journal of physiol… (2004) | pd | 4 | [10.1152/ajpregu.00467.2004](https://doi.org/10.1152/ajpregu.00467.2004) | [15475505](https://www.ncbi.nlm.nih.gov/pubmed/15475505) | metadata signals extractable PD data (EC50) |
| `Yamreudeewong_2003.pdf` | Yamreudeewong W et al., Potentially significant drug interactio…, Drug safety (2003) | pgx | 7 | [10.2165/00002018-200326060-00004](https://doi.org/10.2165/00002018-200326060-00004) | [12688833](https://www.ncbi.nlm.nih.gov/pubmed/12688833) | metadata signals extractable PGX data (CYP1A2, PK/PD-context) |

<sub>queue written 2026-09-19T14:53:59.436810+00:00</sub>

## Screened and excluded

| domain | paper | verdict | relevance | extractability | reason |
|---|---|---|---|---|---|
| popPK | Aussel_1992 | irrelevant | 0 | 0 | The study is an in-vitro mechanistic investigation of phospholipid metabolism in Jurkat T cells, not a pharmacokinetic study, and reports no disposition parameters for bretylium. |
| popPK | Hagelüken_1995 | irrelevant | 0 | 0 | The paper is a mechanistic in-vitro study on G protein activation and does not report any pharmacokinetic parameters for bretylium tosylate. |
| PD | Hagelüken_1995 | not_relevant | 0 | 0 | The paper reports that bretylium tosylate did not increase GTP hydrolysis, providing no numeric PD parameters or concentration-effect relationship for the drug. |
| popPK | Sakuta_1993 | irrelevant | 0 | 0 | The paper is an in-vitro electrophysiology study measuring IC50 values for K+ channel blockade in Xenopus oocytes, not a pharmacokinetic study reporting disposition parameters like clearance or volume. |
| popPK | Wilson_2004 | irrelevant | 0 | 0 | no_text gate: only 80 chars of text extracted (&lt; 400) |
| PD | Wilson_2004 | not_relevant | 0 | 0 | The paper investigates the effect of age on cutaneous vasoconstrictor responses to norepinephrine, not bretylium tosilate. |
| PGx | Yamreudeewong_2003 | not_relevant | 0 | 0 | The paper discusses drug-drug interactions for class III antiarrhythmics but does not report any pharmacogenomic effects (gene variants) on the PK or PD of bretylium tosylate. |

---
<sub>Generated by `docs.py` (scholarv2) · newest extraction 2026-09-19 14:54 UTC</sub>
